GlassScriptPhysician profile
Jason Burklow
NPI 1740600683
$5,055.02
in general payments reported to CMS, 2019-2025
36 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $223 · 2021: $531 · 2022: $407 · 2023: $514 · 2024: $1,096 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,422.42 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $374.52 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $350.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $317.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Noven Therapeutics, LLC | $299.93 | 2023-2025 | Xelstrym, Secuado |
| Esperion Therapeutics, INC. | $243.55 | 2020-2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $236.24 | 2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.05 | 2023-2025 | Jardiance |
| Pfizer INC. | $206.59 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.71 | 2019-2022 | |
| Allergan, INC. | $153.38 | 2019-2020 | |
| Amgen INC. | $98.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.66 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $90.11 | 2019 | |
| Exact Sciences Corporation | $74.32 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Burklow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.